[化学原料和化学制品制造业,医药制造业] [2025-04-30]
Bone cement, which is chemically known as polymethyl methacrylate (PMMA), is widely used for implant fixation in various orthopedic and trauma surgeries and in interventional procedures. Bone cement fixation remains the gold standard for the treatment of many orthopedic disorders and largely contributes to the success of modern joint replacement. Bone cement is widely used in vertebroplasty, a minimally invasive surgical procedure, to treat spinal fractures and collapsed vertebrae.
[医药制造业] [2025-04-29]
1 季度累计数据:多数疫苗品种均同比大幅增长。从 1 季度累计批签发数据来看,多数疫苗品种均同比大幅增长。具体来看,其中猪用疫苗方面,口蹄疫疫 苗、圆环疫苗、伪狂犬疫苗、蓝耳疫苗、猪瘟疫苗、胃腹二联疫苗、猪细小疫苗、猪乙脑疫苗分别同比+3.4%、+46.2%、+38.3%、+8.4%、+35.7%、+44.9%、 +38.1%、+14.8%;禽用疫苗方面,禽流感三价苗、马立克疫苗、新城疫疫苗、鸭传染性浆膜炎疫苗分别同比+22.4%、+4.6%、+10.2%、+54.5%;反刍疫苗方 面,布病疫苗同比+100.0%,小反刍兽疫疫苗同比-44.8%;宠物疫苗方面,国产狂犬疫苗、国产猫三联疫苗分别同比+32.2%、+118.2%。
[医药制造业] [2025-04-27]
我们认为基因测序正在开启全新时代:短期看商务部禁令将大幅加快国产替代进程,中期看 AI 大模型推动测序降本增效实现场景革命,长期看时空组学重构生命科学底层理论研究,几何级别扩容测序量。上游方面,华大智造是全球少有二代测序、四代测序以及时空组学均处于先进地位的测序厂商,首次覆盖给予“买入”评级;中游方面,华大基因在生育健康、肿瘤防治等多领域进行全流程布局,是国产测序服务龙头,首次覆盖给予“增持”评级。
[医药制造业] [2025-04-27]
创新药对外授权交易加速。从2025年初以来,国产创新药企业已经完成了几十笔对外授权的交易,恒瑞医药、联邦制药、和铂医药等均与海外MNC达成了重磅交易。国产创新药的研发进度和临床数据越来越在全球范围内占到优势,创新药BD出海受关税影响较小,有望继续 通过授权出海的形式实现全球的商业化价值。推荐关注具备高质量创新能力的公司:科伦博泰生物、康方生物、三生制药、康诺亚、和黄医药等。
[医药制造业] [2025-04-27]
AACR & ASCO 2025:美国癌症研究协会(AACR)年会是全球规模最大、聚焦基础研究与转化医学的癌症学术会议,旨在推动癌症生物学、早期疗法开发及精准医学的突破性进展。美国临床肿瘤学会(ASCO)年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议。根据各家公司的披露,2025年国内企业有望发布一系列的高质量数据,中国药企持续发力,创新度持续提升,我们持续看好创新药产业技术驱动周期,建议持续关注双抗、ADC及小分子疗法等。
[医药制造业] [2025-04-25]
Dermatology is a field of medicine that deals with the identification, mitigation, and prevention of conditions affecting the skin, hair, nails, and mucous membranes. It entails researching numerous skin problems, including dermatitis, psoriasis, acne, skin cancer, and infectious illnesses. Cosmetic surgeries, such as laser resurfacing, liposuction, and dermal fillers, which are designed to improve skin quality and address skinrelated issues, are also included in the field of dermatology.
[医药制造业] [2025-04-25]
Dietary supplements are manufactured food products that are consumed in addition to regular meals. These supplements provide extra and essential nutrients, which are usually not present in daily meals.
[医药制造业] [2025-04-25]
The direct to consumer laboratory testing market refers to a segment of the healthcare industry that provides individuals with the ability to order and access medical tests and laboratory services directly online without the need for physical visits to hospitals or testing laboratories
[医药制造业] [2025-04-23]
核心观点:关税政策冲击下,对医药产业链的影响较为复杂,并且可能仍然存在变数,因此供应链的自主可控成为产业界和投 资人共同关心的问题。生物制药全产业链装备耗材在过去几年当中国产化率不断提升,但仍存在一定的对外依赖,供应链安全、 成本控制、定制化服务是国产替代的3大核心动力,我们认为耗材及高壁垒设备领域的具有更多投资机会,重点关注平台型公司 及高壁垒细分领域龙头。医疗器械领域建议持续关注美资品牌高值耗材在国内的供货情况、进口替代加速背景下相关上市公司 有较好机会,我们坚定看好器械自主可控及出海的长期趋势。
[医药制造业] [2025-04-23]
本周关税扰动显著,建议底部积极加配医药板块。本周沪深 300 下跌 2.9%,医药生 物下跌 5.6%,处于 31 个一级子行业第 22 位,本周医疗服务、化学制药、医疗器械、 医疗商业、中药、生物制品板块分别下降 11.88%、5.65%、4.92%、3.93%、3.35%、 2.71%。2025 年初到目前的医药板块进行分析,医药板块收益率-1.1%,同期沪深 300 收益率-4.7%,医药板块跑赢沪深 300 收益率 3.6%。本周市场在全球的“对等关税” 政策下出现剧烈调整;美国时间 4 月 8 日,特朗普发表讲话称,美国将对药品征收单 独关税,受此影响医药板块出现进一步下跌。